Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The POET II trial is challenging a 70-year-old standard of care for infective endocarditis. The phase 3 randomized trial found that tailoring antibiotic duration to patient response cut median treatment time from 41 to 26 days — about one-third less — without compromising safety. Researchers say roughly half of all infective endocarditis patients could be candidates for this approach.
The POET II trial is making waves at the European Society of Cardiology Congress 2026 — and in the pages of the New England Journal of Medicine. The phase 3 randomized controlled trial found that tailoring antibiotic therapy for left-sided infective endocarditis based on patient response significantly cut treatment duration without sacrificing safety, potentially rewriting a standard that's been in place since the 1950s.
In the trial, 508 patients with stable infective endocarditis caused by S. aureus, E. faecalis, or Streptococcus species were randomized after meeting clinical stabilization criteria on at least 2 weeks of IV antibiotics. Those in the tailored arm stopped antibiotics at a median of 26 days vs. 41 days in the standard arm. The primary safety endpoint — unplanned cardiac surgery or symptomatic embolic events at 6 months — was met with noninferiority (8.2% vs. 10.7%). One caveat: relapse of bacteremia or endocarditis was higher in the tailored group (5.1% vs. 1.6%), though most cases were uncomplicated and managed without surgery.
Key Takeaways:
Why it matters: Shorter antibiotic courses mean less time in the hospital, fewer drug-related side effects, lower costs, and reduced risk of antimicrobial resistance — all meaningful wins for patients and health systems alike. But experts caution this isn't a one-size-fits-all solution; it requires the right patient, the right team, and the right infrastructure.
